Two announcements from different regions in May 2026 have outlined a clear commercial picture for the AI healthcare sector. On one end was a key breakthrough in a developed market. On May 6, YIDU TECH announced that its subsidiary successfully won the bid for the Dr Buddy project of SingHealth, Singapore's largest public healthcare group, with a contract value of approximately 12.2 million RMB. This project is a key application of Singapore's National Mobile Inpatient Care Plan, serving institutions including the world-renowned Singapore General Hospital. This marks the first time a Chinese AI healthcare solution has systematically entered the core operational scenarios of the mainstream healthcare system in a developed country. On the other end was China's top-tier medical high ground. Around the same time, the 9.08 million RMB smart clinical upgrade project of Sun Yat-sen University Cancer Center also went to YIDU TECH. This represents another deep repurchase by a top-tier institution for this AI healthcare leader, following its recent wins of the AI large model project from Peking University Cancer Hospital and the clinical trial SMO project from The First Affiliated Hospital of Guangzhou Medical University within a short span of a month.
The concentrated landing of these orders is not an isolated event. Just about a month prior, YIDU TECH released its most milestone financial forecast since its founding over a decade ago: it expects to achieve a net profit of 55 to 70 million RMB for the 2026 fiscal year. This signifies that this company, which has long invested in medical data intelligence infrastructure, has crossed the threshold to annual profitability for the first time. From top-tier Class A hospitals in Beijing and Guangzhou, to a provincial public health platform in Hainan, and then to a national-level project in Singapore, penetrating both high-barrier domestic and international markets within less than a month, coupled with the profitability expectation, signals for YIDU TECH that its over-a-decade-long "infrastructure" construction has finally crossed the commercialization tipping point. The company's development narrative has thus completed a crucial shift from painting a vision of "technological possibility" to becoming a practical case study validating a "product marketization" path. It demonstrates how to transform complex technological capabilities into a product system that systematically addresses core pain points in clinical practice, research, and management, while simultaneously penetrating globally high-barrier markets.
**Accelerating Orders and "Deep Repurchases" from Top Hospitals** The most stringent criterion for judging a B2B healthcare technology company is arguably the repurchase rate from top-tier hospitals. Among YIDU TECH's recent project wins, the most telling aspect is not the contract value itself, but the depth and continuity of the partnerships. The projects cover a diverse range of scenarios: from top specialist hospitals to leading comprehensive hospitals, from provincial public health platforms to overseas national projects, and from clinical research to hospital operations. This indicates its solutions possess strong cross-scenario and cross-regional adaptability. A deeper analysis reveals a prominent feature: deep integration and sustained repurchases. Whether it's the decade-long collaboration with SYSUCC, the recent AI project win, or the continuation from PIONEER to PIONEER2 with The First Affiliated Hospital of Guangzhou Medical University, it shows partnerships have evolved from one-off project purchases to strategic co-development based on long-term trust and mutual growth. In fact, within the highly exclusive environment of top-tier Class A hospitals, securing continuous "repurchases" from these institutions and their experts is far more challenging than initial access. Taking SYSUCC's 9.08 million RMB smart clinical upgrade project as an example, the collaboration has progressed from an early oncology big data platform, to private deployment of an AI middle platform, and now to an integrated AI management system. Each upgrade revalidates the product's value—when AI tools tangibly enhance doctors' research efficiency, optimize clinical pathways, and even aid hospitals in precise cost control under DRG/DIP payment reforms, they transition from "optional" to "essential."
If domestic top hospital orders validate the product's necessity, then projects like Brunei's BruHealth national health management platform covering 85% of the population and Singapore's SingHealth Dr Buddy project represent YIDU TECH's crucial leap in commercial international expansion. In a market long dominated by Siemens, GE, and Philips, a Chinese AI company securing the implementation and delivery rights for a national core project serves as the most powerful endorsement of its technological capabilities. Gaining entry into such a system signifies YIDU TECH's products have attained international-grade delivery capabilities—a rarity within the Hong Kong-listed AI healthcare sector. Most notably, the scale and level of YIDU TECH's orders over this past month have significantly increased. Multi-million RMB orders have become frequent, and project natures have evolved from modular function development to system-level engineering like "smart clinical and settlement service upgrades" and co-building overall paradigms like "AI hospitals." This confirms hospital clients' recognition of its holistic solutions, with average revenue per user (ARPU) continuously rising.
Simultaneously, a profound transformation in the quality of the company's revenue cannot be overlooked. YIDU TECH has been the primary operator for "Shenzhen Hui Min Bao" for four consecutive years. Leveraging YiduCore, it has built intelligent risk prediction and management capabilities for tens of millions of people, deeply participating in Hui Min Bao projects across 5 provinces and 13 cities, cumulatively serving over 45 million insured users. This "technology platform + continuous operation" model, together with AI middle platform subscription services for hospitals and dataset solutions for pharmaceutical companies, forms a diverse and highly sticky revenue portfolio. The commercial snowball begins rolling with sustained effort on a long slope. With its product strength validated in top hospitals, YIDU TECH's network of over ten thousand covered hospitals and its deep cooperative relationships with a host of China's top medical institutions and regulatory bodies are transforming from "benchmark cases" into a "foundation for scaled replication."
**Commercial Elevation: Closing the "Hospital-Patient-Pharma" Value Loop** The hardest barrier in AI healthcare commercialization is not technology demonstration, but integration into core hospital workflows, genuine clinical adoption, and willingness for continuous payment. The concentrated landing of top hospital orders for YIDU TECH since 2026 is essentially the result of its product strength completing closed-loop validation in real clinical settings. Taking SYSUCC as an example, the collaboration started in 2015, progressing from co-building an oncology big data platform, to private deployment of an AI middle platform in February 2026, to the current 9.08 million RMB smart clinical and settlement upgrade project. The collaboration depth has moved from the "data layer" into the "business operation layer." This means YIDU TECH's products are no longer peripheral tools but core infrastructure embedded into the entire chain of diagnosis, treatment, research, and management. The concurrent landing of the AI large model specialist application project at PKUCH points to a clear trend: top oncology specialty hospitals are transitioning AI from "pilots" to "standard equipment," upgrading from "single-point trials" to hospital-wide, specialty-specific, and process-integrated deployment. These continuous repurchases from top hospitals reflect a fact long underestimated by the market: the demand for AI among China's Class A hospitals has shifted from "whether to use it" to "whose to use and how to use it deeply."
Therefore, YIDU TECH's profitability does not stem from the accidental success of a single "hit" application, but rather from the systematic value output loop finally formed across multiple dimensions by the "unified evidence infrastructure" it has built over many years. This loop is centrally embodied in the three major solution suites released at the CHIMA conference and validated in the recent series of project wins. These products and solutions are not isolated modules; they are all rooted in YIDU TECH's unified YiduCore data intelligence foundation, which has cumulatively processed and analyzed nearly 7 billion medical records. Precisely based on this profound data governance and AI capability, YIDU TECH is constructing a rigorous "data-to-scenario" flywheel logic: the underlying high-quality data and evidence capabilities continuously nourish the upper-layer applications, while the rich scenarios spanning clinical practice, research, and management, in turn, feed back to the underlying models, enabling their continuous iterative evolution based on real-world feedback. This mutually reinforcing flywheel effect thoroughly bridges the data silos between hospitals, doctors, pharmaceutical companies, and patients.
For instance, products like the AI Middle Platform 3.0 and Clinical Assistant Copilot 2.0 transform AI from "demonstration value" to "efficiency value": AI empowers doctors' daily workflows across diagnosis, medical records, orders, follow-ups, and research. Daily invocation counts in the thousands and coverage of 70% of medical staff are no longer isolated cases but the norm in benchmark hospitals. Products like the clinical evidence-based intelligent agent deeply integrate globally authoritative guidelines and high-quality literature into the diagnostic and treatment process, providing doctors with decision support where "every statement is evidence-based." The new-generation operation data center drives hospitals to achieve cost reduction, efficiency improvement, and refined operations with trusted data. The high-quality dataset solutions based on research-specific disease databases unlock the value pathway from data as a resource to data as an asset. When products genuinely solve the rigid pain points of "doctor fatigue, difficult decisions, and slow research," willingness to pay, repurchase rates, and customer unit prices naturally rise in tandem—this is the underlying logic why top hospitals are willing to make continuous, multi-stage, substantial investments.
Looking at future commercial space, the systematic deployment capability and practical product value YIDU TECH has demonstrated within top hospital systems extend far beyond clinical department applications in benchmark institutions. China's vast market of over 13,000 secondary and above hospitals holds even greater potential for trillion-RMB derivative markets like pharmaceutical R&D and commercial insurance, leveraged through data elementization. Relying on the unified evidence foundation built through years of深耕 and a complete product matrix covering core hospital scenarios, YIDU TECH has secured an advantageous position in this race "from technology to scenario."
**Profitability Inflection Point: From "Project-Based" to an "Ecosystem" Flywheel** The密集 orders and technological breakthroughs have ultimately converged into a bright inflection point on the financial statements. YIDU TECH expects a net profit of 55 to 70 million RMB for the 2026 fiscal year. Delving deeper into the financial data reveals an even more striking picture: for the first half of FY2026, YIDU TECH reported a net loss of 15.76 million RMB. This implies that in the second half alone, the company achieved a remarkable profit ranging from 70.76 to 85.76 million RMB. The emergence of this profitability inflection point is not accidental. It stems from the synergistic爆发 across the entire "hospital-pharma-insurance-patient" ecosystem链: On the "hospital" end, the AI middle platform and clinical intelligent agents are scaling within top hospitals. On the "patient" end, the company operates tens of millions of active users through inclusive insurance programs like Hui Min Bao. On the "pharma" end, real-world research continuously empowers new drug development, shortening R&D cycles for pharmaceutical companies. The parallel advancement of these three business segments has freed the company from the constraints of a单一 project-based model, forming a high-margin, replicable standardized product revenue structure. Once established, the momentum of this "snowball"盈利 growth model is formidable. Conservatively estimating, even if maintaining the profitability level of the second half of FY2026, YIDU TECH's full-year profit for FY2027 could potentially reach 141 to 170 million RMB.
The significance of profitability extends far beyond the financial figures themselves. It signals a fundamental shift in the market's valuation logic for YIDU TECH—from price-to-sales (PS) to price-to-earnings (PE). Referring to profitable AI healthcare peers in Hong Kong, the current PE multiple center for profitable companies in the sector is approximately 30 to 45 times. In a recent research report, Citigroup pointed out that based on a sum-of-the-parts valuation, the big data platform, life sciences, health management segments, and net cash contribute HK$2.8, HK$2.0, HK$2.7, and HK$3.4 per share respectively, indicating ample safety margin. Furthermore, the company has conducted 34 share buybacks year-to-date, amounting to nearly HK$240 million—the highest buyback intensity in the Hong Kong-listed AI healthcare sector. With a cash reserve of nearly 3.7 billion RMB, the company is well-equipped to provide ample ammunition for further technological and market深耕.
**Conclusion** From the specialist intelligent agents at PKUCH, to the AI hospital model at The Second Affiliated Hospital of Chongqing Medical University, and then to the transnational project in Singapore, YIDU TECH is replicating its validated "evidence infrastructure" capability from individual departments and single hospitals to regional and even national levels, and from domestic to international markets. This transformation process clearly outlines its deeper strategic vision—to become the "AI operating system for Chinese hospitals." Just as personal computers离不开 Windows or macOS, future smart hospitals will inevitably run on a unified intelligent foundation. What YIDU TECH is building is precisely such a "core system" capable of向下兼容 vast heterogeneous medical data while向上 supporting countless application ecosystems for clinical practice, research, management, and more. It no longer aims to be merely a piece in the hospital informatization puzzle but strives to become the central nervous system driving the entire hospital's intelligent operation. As the founder emphasized in an internal sharing, profitability is not a financial终点 but a signal that "a medical evidence infrastructure built over more than a decade is beginning to possess self-sustaining operational capability." As this "AI operating system" takes root in more and more hospitals and achieves self-iteration, its network effects will be released exponentially. This closed loop from "burning cash on R&D" to "self-generating造血" is precisely the拐点 most anticipated by the capital market. Hence, the "Buy" rating with an HK$11 target price reiterated by Citigroup and the "Outperform" recognitions from several institutions over the past month represent the capital market's belated acknowledgment of this flywheel effect.
Comments